BioNeutra Global Corporation
BGACF
$0.0608
$0.0386173.87%
| Weiss Ratings | BGACF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | BGACF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BGACF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.84 | |||
| Price History | BGACF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -0.08% | |||
| 30-Day Total Return | -0.08% | |||
| 60-Day Total Return | 360.23% | |||
| 90-Day Total Return | 1,635.71% | |||
| Year to Date Total Return | 203.75% | |||
| 1-Year Total Return | 1,635.71% | |||
| 2-Year Total Return | -51.40% | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | 0.00% | |||
| 52-Week Low % Change | 360.23% | |||
| Price | BGACF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.06 | |||
| 52-Week Low Price | $0.01 | |||
| 52-Week Low Price (Date) | Jan 10, 2024 | |||
| 52-Week High Price (Date) | Feb 15, 2024 | |||
| Valuation | BGACF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.55M | |||
| Enterprise Value | 8.13M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.08 | |||
| Earnings Per Share Growth | 86.49% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.34 | |||
| Price/Book (Q) | -0.51 | |||
| Enterprise Value/Revenue (TTM) | 0.89 | |||
| Price | $0.06 | |||
| Enterprise Value/EBITDA (TTM) | -3.21 | |||
| Enterprise Value/EBIT | -2.42 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BGACF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 46.70M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BGACF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 604 210 5669 | |||
| Address | 1101-1030 West Georgia Street Vancouver, BC V6E 2Y3 | |||
| Website | www.bioneutra.ca | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | BGACF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -36.74% | |||
| Profit Margin | -41.81% | |||
| Management Effectiveness | BGACF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -13.33% | |||
| Return on Equity | -- | |||
| Income Statement | BGACF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 8.35M | |||
| Total Revenue (TTM) | 8.35M | |||
| Revenue Per Share | $0.18 | |||
| Gross Profit (TTM) | 887.00K | |||
| EBITDA (TTM) | -2.32M | |||
| EBIT (TTM) | -3.07M | |||
| Net Income (TTM) | -3.49M | |||
| Net Income Avl. to Common (TTM) | -3.49M | |||
| Total Revenue Growth (Q YOY) | -25.00% | |||
| Earnings Growth (Q YOY) | -5.54% | |||
| EPS Diluted (TTM) | -0.08 | |||
| EPS Diluted Growth (Q YOY) | 2.61% | |||
| Balance Sheet | BGACF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 585.30K | |||
| Cash Per Share (Q) | $0.01 | |||
| Total Current Assets (Q) | 4.82M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -5.54M | |||
| Current Ratio (Q) | 0.392 | |||
| Book Value Per Share (Q) | -$0.12 | |||
| Total Assets (Q) | 11.67M | |||
| Total Current Liabilities (Q) | 12.31M | |||
| Total Debt (Q) | 5.25M | |||
| Total Liabilities (Q) | 17.21M | |||
| Total Common Equity (Q) | -5.54M | |||
| Cash Flow | BGACF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 9.20K | |||
| Cash from Financing (TTM) | -126.50K | |||
| Net Change in Cash (TTM) | 39.70K | |||
| Levered Free Cash Flow (TTM) | 2.24M | |||
| Cash from Operations (TTM) | 1.01M | |||
